Female and male subjects of childbearing potential must agree to use an adequate method of contraception, prior to study entry, for the duration of study participation, and  months after completion of pembrolizumab administration; contraception is required starting with the first dose of study medication through  days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
Female and male subjects of childbearing potential must agree to use an adequate method of contraception; contraception is required prior to study entry and for the duration of study participation and  months after completion of pembrolizumab administration; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
Female and male subjects of childbearing potential must agree to use an adequate method of contraception; contraception is required starting with the first dose of study medication through  days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
Male subjects must agree to use adequate contraception (e.g., condoms; abstinence) for the duration of study treatment and  months after completion
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before to study entry and for the duration of study participation; female patients of childbearing potential must have a negative urine or serum pregnancy test within  hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient; male patients of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception before the study, for the duration of study participation, and  months after completion of MK- (pembrolizumab) and interferon-gamma administration
